<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>OBIZUR- antihemophilic factor porcine, b-domain truncated recombinant 
			 </strong><br>Baxter Healthcare Corporation<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use OBIZUR safely and effectively.  See full prescribing information for OBIZUR.<br>OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence] <br>Lyophilized Powder for Solution for Intravenous Injection<br>Initial U.S. Approval: 2014</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">OBIZUR, Antihemophilic Factor (Recombinant), Porcine Sequence, is an antihemophilic factor indicated for the treatment of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes in adults with acquired <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>. (1)  (<a href="#section-1">1</a>)</p>
<p class="Highlighta">Limitations of Use:  (<a href="#section-1">1</a>)</p>
<dl>
<dt>•</dt>
<dd>Safety and efficacy of OBIZUR has not been established in patients with a baseline anti-porcine factor VIII inhibitor titer of greater than 20 BU. (1)</dd>
<dt>•</dt>
<dd>OBIZUR is not indicated for the treatment of congenital <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> or von Willebrand disease. (1)</dd>
</dl>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">For intravenous use after reconstitution only (2)</span>  (<a href="#section-2">2</a>)</p>
<dl>
<dt>•</dt>
<dd>Initial dose of OBIZUR is 200 units per kg. (2.1)</dd>
<dt>•</dt>
<dd>Titrate dose and frequency of administration based on factor VIII recovery levels and individual clinical response. (2.1)</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">OBIZUR is available as lyophilized powder for solution in single-use vials containing nominally 500 units per vial. (3)  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Do not use in patients who have had life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to OBIZUR or its components, including hamster protein. (4)  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, may occur. Should symptoms occur, discontinue OBIZUR and administer appropriate treatment. (5.1)</dd>
<dt>•</dt>
<dd>Development of inhibitory antibodies to OBIZUR has occurred. If expected plasma factor VIII activity levels are not attained, or if <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is not controlled with an appropriate dose, perform an assay that measures porcine factor VIII inhibitor concentration. (5.2)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Common adverse reaction observed in greater than 5% of subjects in the clinical trial were development of inhibitors to porcine factor VIII. (6.1) </p>
<p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare Corporation at 1-866-888-2472 or FDA at 1-800-FDA-1088 or <span class="Bold"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt> </dt>
<dd>Pregnancy: No human or animal data. Use only if clinically needed. (8.1)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 10/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Reconstitution</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2  Inhibitory Antibodies</a></h2>
<h2><a href="#section-5.3" class="toc">5.3  Monitoring Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-9.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h1><a href="#section-10" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-11" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-12" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-13" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_aaf5683a-8673-437e-b1f0-e8b54ad65117"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">OBIZUR, Antihemophilic Factor (Recombinant), Porcine Sequence, is a recombinant DNA derived, antihemophilic factor indicated for the treatment of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes in adults with acquired <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>. </p>
<p>Limitations of Use:</p>
<dl>
<dt>•</dt>
<dd>Safety and efficacy of OBIZUR has not been established in patients with baseline anti- porcine factor VIII inhibitor titer greater than 20 BU. </dd>
<dt>•</dt>
<dd>OBIZUR is not indicated for the treatment of congenital <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> or von Willebrand disease.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_90ca9f1c-a3dc-4c6d-8355-6a991035a355"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">For intravenous use after reconstitution only</span></p>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_83aa31a5-fa80-4630-8df5-5985c3449f86"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dose</h2>
<dl>
<dt>•</dt>
<dd>Dose, dosing frequency, and duration of treatment with OBIZUR depend on the location and severity of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episode, target factor VIII levels, and the patient’s clinical condition.  Monitor replacement therapy in cases of major surgery or life-threatening <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes.</dd>
<dt>•</dt>
<dd>Each vial of OBIZUR has the recombinant porcine factor VIII potency in units stated on the vial.</dd>
<dt>•</dt>
<dd>Patients may vary in their pharmacokinetic (e.g., half-life, in vivo recovery) and clinical responses. Titrate dose and frequency based on factor VIII recovery levels and individual clinical response.</dd>
</dl>
<p class="First">A guide for dosing OBIZUR for the treatment and prevention of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes is provided in Table 1. Maintain the factor VIII activity within the target range. Plasma levels of factor VIII should not exceed 200% of normal or 200 units per dL.</p>
<table width="517.5pt">
<caption><span>Table 1 Dosing for Treatment of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Episodes</span></caption>
<col width="24%">
<col width="18%">
<col width="10%">
<col width="27%">
<col width="21%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Type of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First"><span class="Bold">Factor VIII Level Required (Units per dL or % of normal)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Initial Dose (Units per kg)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Subsequent Dose</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Frequency and Duration of Subsequent Dosing</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Minor and Moderate</span> Superficial muscle/no neurovascular compromise, and joint</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">50-100</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle"><p class="First">200</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle"><p class="First">Titrate subsequent doses to maintain recommended factor VIII trough levels and individual clinical response</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle"><p class="First">Dose every 4 to 12 hours, frequency may be adjusted based on clinical response and measured factor VIII levels</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Major</span></p>
<p>Moderate to severe intramuscular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, retroperitoneal, gastrointestinal, intracranial</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">100-200 (To treat an acute bleed)</p>
<p>50-100 (After acute bleed is controlled, if required)</p>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_cbc6afb3-4845-4b0a-8c4b-3537ad46aa35"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Reconstitution</h2>
<dl>
<dt>•</dt>
<dd>Use aseptic technique during the reconstitution procedure.</dd>
<dt>•</dt>
<dd>If the patient needs more than one vial of OBIZUR per injection, reconstitute each vial according to the following instructions:</dd>
</dl>
<dl>
<dt>1.</dt>
<dd>Bring the OBIZUR vial and the pre-filled diluent syringe to room temperature. </dd>
<dt>2.</dt>
<dd>Remove the plastic cap from the OBIZUR vial (Figure A). </dd>
<dt>3.</dt>
<dd>Wipe the rubber stopper with an alcohol swab (not supplied) and allow it to dry prior to use.</dd>
<dt>4.</dt>
<dd>Peel back the cover of the vial adapter package (Figure B). Do not to touch the luer-lock (tip) in the center of the vial adapter. Do not remove the vial adapter from the plastic package. </dd>
<dt>5.</dt>
<dd>Place the vial adapter package on a clean surface with the luer-lock pointing up.</dd>
<dt>6.</dt>
<dd>Snap off the tamper resistant cap of the pre-filled syringe (Figure C).</dd>
<dt>7.</dt>
<dd>While firmly holding the vial adapter package, connect the pre-filled syringe to the vial adapter by pushing the syringe tip down onto the luer lock in the center of the vial adapter, and turning it clockwise until the syringe is secured. Do not over tighten (Figure D).</dd>
<dt>8.</dt>
<dd>Remove the plastic package (Figure E).</dd>
<dt>9.</dt>
<dd>Place the OBIZUR vial on a clean, flat, hard surface. Place the vial adapter over the OBIZUR vial and firmly push the filter spike of the vial adapter through the center of the OBIZUR vial’s rubber circle until the clear plastic cap snaps onto the vial (Figure F).</dd>
<dt>10.</dt>
<dd>Push the plunger down to slowly inject all of the diluent from the syringe into the OBIZUR vial.</dd>
<dt>11.</dt>
<dd>Gently swirl (in a circular motion) the OBIZUR vial without removing the syringe until all of the powder is fully dissolved (Figure G). The reconstituted solution should be inspected visually for particulate matter before administration. Do not use if particulate matter or discoloration is observed.</dd>
<dt>12.</dt>
<dd>With one hand hold the vial and vial adapter, and with the other hand firmly grasp the barrel of the pre-filled syringe and in a counterclockwise motion unscrew the syringe from the vial adapter (Figure H).</dd>
<dt>13.</dt>
<dd>Use OBIZUR within 3 hours after reconstitution when stored at room temperature.</dd>
</dl>
<div class="Figure">
<a name="id596449064"></a><img alt="Figure A through H .jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69ccbb3-7648-4978-8c6d-7ca6b95a9b01&amp;name=image-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_32d28b4c-290f-49da-b6e8-3416316a2d2e"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Administration</h2>
<p class="First"><span class="Bold">For intravenous injection only</span></p>
<dl>
<dt>•</dt>
<dd>Inspect the reconstituted OBIZUR solution for particulate matter and discoloration prior to administration. The solution should be clear and colorless in appearance. Do not administer if particulate matter or discoloration is observed. </dd>
<dt>•</dt>
<dd>Do not administer OBIZUR in the same tubing or container with other medicinal products for infusion.</dd>
</dl>
<dl>
<dt>1.</dt>
<dd>Once all vials have been reconstituted, connect a large syringe to the vial adapter by gently pushing the syringe tip down onto the luer lock in the center of the vial adapter, and turning clockwise until the syringe is secured. </dd>
<dt>2.</dt>
<dd>Invert the vial; push the air in the syringe into the vial and withdraw the reconstituted OBIZUR into the syringe (Figure I).</dd>
</dl>
<div class="Figure">
<a name="id527"></a><img alt="Figure 1.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69ccbb3-7648-4978-8c6d-7ca6b95a9b01&amp;name=image-02.jpg"><p class="MultiMediaCaption">Figure I </p>
</div>
<dl>
<dt>3.</dt>
<dd>Unscrew the large syringe counterclockwise from the vial adapter, and repeat this process for all reconstituted vials of OBIZUR until the total volume to be administered is reached.</dd>
<dt>4.</dt>
<dd>Administer the reconstituted OBIZUR intravenously at a rate of 1 to 2 mL per minute. </dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_ae935415-5cff-4ed2-960f-18c8aa5f354e"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">OBIZUR is available as a white lyophilized powder in single-use glass vials containing nominally 500 units per vial.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_9fbcbe2f-fb9d-4131-9daf-42d6abd59a90"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">OBIZUR is contraindicated in patients who have had life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to OBIZUR or its components (including traces of hamster proteins).</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_ffffeed0-84e6-4504-bca3-ff73b7f73478"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_aa3575f1-1b6e-4dd7-b16c-9a5f5f6dcb75"></a><a name="section-5.1"></a><p></p>
<h2>5.1  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> can occur with OBIZUR. OBIZUR contains trace amounts of hamster proteins. Early signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, which can progress to <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, include <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, chest-tightness, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. Immediately discontinue administration and initiate appropriate treatment if allergic or anaphylactic-type reactions occur.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_0d72100f-218d-4a72-b5e0-b1a64735155c"></a><a name="section-5.2"></a><p></p>
<h2>5.2  Inhibitory Antibodies</h2>
<p class="First">Inhibitory antibodies to OBIZUR have occurred. Monitor patients for the development of antibodies to OBIZUR by appropriate assays [see<span class="Italics"> Monitoring Laboratory Tests (5.3)</span>].  If the plasma factor VIII level fails to increase as expected, or if <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is not controlled after OBIZUR administration, suspect the presence of an anti-porcine factor VIII antibody. If such inhibitory antibodies to anti-porcine factor VIII are suspected and there is a lack of clinical response, consider other therapeutic options.<span class="Italics"></span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_a8038487-30d0-4c8b-b193-39aa9ab84a3d"></a><a name="section-5.3"></a><p></p>
<h2>5.3  Monitoring Laboratory Tests</h2>
<dl>
<dt>•</dt>
<dd>Perform one-stage clotting assay to confirm that adequate factor VIII levels have been achieved and maintained [see<span class="Italics"> Dosage and Administration (2)</span>].<dl>
<dt>o</dt>
<dd>Monitor factor VIII activity 30 minutes and 3 hours after initial dose.</dd>
<dt>o</dt>
<dd>Monitor factor VIII activity 30 minutes after subsequent doses.</dd>
</dl>
</dd>
<dt>•</dt>
<dd>Monitor the development of inhibitory antibodies to OBIZUR. Perform a Nijmegen Bethesda inhibitor assay if expected plasma factor VIII activity levels are not attained or if <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is not controlled with the expected dose of OBIZUR. Use Bethesda Units (BU) to report inhibitor levels.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_974d3e4b-20e7-434a-a7ed-875dab5cc08f"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Common adverse reactions observed in greater than 5% of subjects in the clinical trial were development of inhibitors to porcine factor VIII.</p>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_ad80b820-bb8e-436b-9742-f15fc60dc0ff"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction (AR) rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The safety and efficacy  of OBIZUR was evaluated in a multi-center, prospective, open-label, clinical trial that investigated adult patients with acquired <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>. Twenty-nine adult subjects were enrolled in the study, received at least one dose of OBIZUR and were evaluable for safety [see<span class="Italics"> Clinical Studies (14)</span>]. Of the 29 adult subjects, 10 were between the ages of 40 and 65, and 19 were 65 years of age or older (18 Caucasian, 6 African-American, and 5 Asian). Ten (34%) subjects were female.</p>
<p>The most frequently reported adverse reaction in patients with acquired <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> was the development of inhibitors to porcine factor VIII. </p>
<p><span class="Italics">Immunogenicity</span></p>
<p>All subjects were monitored for development of inhibitory antibodies to OBIZUR using the Nijmegen modification of the Bethesda inhibitor assay. A subject was considered to have developed an OBIZUR inhibitor if the titer was ≥0.6 Bethesda Units (BU)/mL.  </p>
<p>Of the 29 subjects treated with OBIZUR, 19 subjects were negative for anti-porcine factor VIII antibodies at baseline. Five of the 19 (26%) developed anti-porcine factor VIII antibodies following exposure to OBIZUR. Of the 10 subjects with detectable anti-porcine factor VIII antibodies at baseline, 2 (20%) experienced an increase in titer and eight (80%) experienced a decreasing to a non-detectable titer.</p>
<p>All subjects were also monitored for development of binding antibodies to baby hamster kidney (BHK) protein by a validated sequential ELISA (enzyme-linked immunosorbent assay).  No patients developed <span class="Italics">de novo</span> anti-BHK antibodies.</p>
<p>The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to OBIZUR with the incidence of antibodies to other products may be misleading.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_bedf006d-faf7-49e5-9b28-3cacc911feca"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_98a8a294-0406-4b47-9362-7cd809dc21d1"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category C</span></p>
<p>Animal reproduction studies have not been conducted with OBIZUR. It is also not known whether OBIZUR can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. OBIZUR should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_9a277d49-205f-4c8a-8a0c-0a504bbb4bcf"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted into human milk. Because many drugs are excreted into human milk, caution should be exercised if OBIZUR is administered to nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_832b2386-34d5-47b8-9b64-9a5c7dd19791"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and efficacy of OBIZUR have not been established in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_d1268e3d-493c-4332-b26a-69707f33d449"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 29 subjects within the trial, the average age was 70 years of age. Nineteen subjects were 65 years of age or older. Clinical studies suggest that OBIZUR is safe and effective in the adult population [see Adverse Reactions (6) and Clinical Studies (14)].  While no differences were observed between geriatric and adult responses to OBIZUR, these findings are inconclusive given the small number of subjects enrolled in either group.  </p>
<p>Dose adjustments in the geriatric population have not been studied. Specific hazards associated with the concomitant use of OBIZUR with other drugs in the elderly population have not been studied in the clinical trial</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_aaf51b54-8189-48f2-8a0a-082147f93ab8"></a><a name="section-8"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">The active ingredient in OBIZUR is a recombinant (r) analogue of porcine factor VIII (pFVIII) with an approximate molecular weight of 170 kDa. The rpFVIII molecule in OBIZUR is a glycoprotein containing a 90 kDa heavy chain and a 80 kDa light chain. The B-domain normally present in naturally occurring porcine factor VIII has been replaced with a twenty-four amino acid linker. Once activated, the resulting rpFVIIIa has a comparable activity to the endogenous human FVIIIa. </p>
<p>OBIZUR is expressed in a genetically engineered baby hamster kidney (BHK) cell line which secretes rpFVIII into the cell culture medium, and the rpFVIII protein is purified using a series of chromatography and filtration steps. The production process includes two dedicated viral clearance steps - a solvent/detergent treatment step for viral inactivation and a nanofiltration step through a series of two 15-nm filters for removal of viruses. No additives of human or animal origin are used in the formulation of OBIZUR.</p>
<p>OBIZUR is formulated as a sterile, non-pyrogenic, lyophilized powder for intravenous injection after reconstitution with the diluent (Sterile Water for Injections). OBIZUR is available in single-use vials that nominally contain 500 units (U) per vial. When reconstituted with the diluent, the product contains the following components per mL: 8.8 mg sodium chloride, 0.04 mg Tris-base, 0.73 mg Tris-HCl, 1.47 mg tri-sodium citrate dehydrate, 0.15 mg calcium chloride dehydrate, 1.9 mg sucrose, and 0.05 mg polysorbate 80.  </p>
<p>Each vial of OBIZUR is labeled with the actual rpFVIII activity expressed in units determined by a one-stage clotting assay, using a reference rpFVIII material calibrated against the World Health Organization (WHO) 8th International Standard for human FVIII concentrates. The specific activity of OBIZUR is in the range of 11000 - 18000 U per milligram of protein. The potency values of OBIZUR determined by the chromogenic assay vary and are approximately 20-50 % lower than those of the one-stage clotting assay.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_8d75f729-f328-491d-936c-d387d9bd6144"></a><a name="section-9"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_27dcf2fb-7080-4002-b558-8405c58a52d2"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">OBIZUR temporarily replaces the inhibited endogenous factor VIII that is needed for effective hemostasis in patients with acquired <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_adf8f273-968b-44ab-a623-f8bd229f0962"></a><a name="section-9.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Patients with acquired <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> (AHA) have normal factor VIII genes but develop autoantibodies against their own factor VIII (i.e., inhibitors). These autoantibodies neutralize circulating human factor VIII and create a functional deficiency of this procoagulant protein. AHA results in a prolonged clotting time as measured by the <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin time</span> (aPTT) assay, a conventional in vitro test for biological activity of factor VIII.  Treatment with OBIZUR should normalize the aPTT during treatment; however aPTT normalization should not be used as a measure of efficacy.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_0182bb1c-c3a9-46ab-99b9-ead514311665"></a><a name="section-10"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_7d8fe0d5-e4de-4b74-acc5-1c258ceb1d6d"></a><a name="section-10.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals to evaluate the carcinogenic potential of OBIZUR, or studies to determine genotoxicity and the effects of OBIZUR on fertility, have not been performed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_03a99adf-e945-4945-a90f-20668fa1243e"></a><a name="section-11"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The efficacy of OBIZUR for the treatment of serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes in subjects with acquired <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> was investigated in a prospective, open-label trial (N=29). The trial was conducted in 18 Caucasian, 6 African-American, and 5 Asian subjects diagnosed with acquired <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> (AHA), having auto-immune inhibitory antibodies to human factor VIII, and experiencing serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes that required hospitalization. Subjects with a prior history of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorders other than AHA, anti-porcine factor VIII antibody titer &gt; 20 Bethesda Units (BU), or in whom the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episode was judged likely to resolve on its own were excluded. One subject was considered evaluable at study entry; however, it was later determined that this subject did not have AHA, leaving 28 subjects evaluable for efficacy.</p>
<p>An initial dose of 200 units per kg OBIZUR was administered to subjects for the treatment of life- or limb-threatening initial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes. Patients were treated with</p>
<p>OBIZUR until resolution of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or dosing was continued at the physician’s discretion according to the clinical assessment. These <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes included 19 intramuscular or joint <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes, 4 post-surgical <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes, 2 intracranial episodes, 2 surgeries, 1 <span class="product-label-link" type="condition" conceptid="4318539" conceptname="Retroperitoneal hemorrhage">retroperitoneal hemorrhage</span>, and 1 periorbital bleed. Hemostatic response was assessed by the study site investigator at specified time points after initiation of OBIZUR treatment using a pre-specified rating scale that was based on subjective clinical assessments combined with objective factor VIII activity levels achieved. An assessment of effective or partially effective was considered as a positive response (see Table 2 for definitions).</p>
<table width="100%">
<caption><span>Table 2 Response to OBIZUR Treatment Evaluation</span></caption>
<col width="15%">
<col width="21%">
<col width="31%">
<col width="13%">
<col width="11%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Assessment of efficacy</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Control of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Clinical Assessment</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Factor VIII levels</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Response</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>Effective</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> stopped </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">clinical control</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">≥50%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">positive</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Partially effective</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> reduced </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">clinical stabilization or improvement; or alternative reason for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">≥ 20%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">positive</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Poorly effective</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> slightly reduced or unchanged</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">not clinically stable</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">&lt;50%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">negative</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Not effective</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> worsening</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Clinically deteriorating</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">&lt;20%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">negative</p></td>
</tr>
</tbody>
</table>
<p>Of the 28 subjects evaluable for efficacy, all subjects had a positive response to treatment for the initial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes at 24 hours after dosing. A positive response was observed in 95% (19/20) of subjects evaluated at 8 hours and 100% (18/18) at 16 hours. </p>
<p>In addition to response to treatment, the overall treatment success was determined by the investigator based on his/her ability to discontinue or reduce the dose and/or dosing frequency of OBIZUR. A total of 24/28 (86%) had successful treatment of the initial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episode. Of those subjects treated with OBIZUR as first-line therapy, defined as no immediate previous use of anti-hemorrhagic agents prior to the first OBIZUR treatment, 16/17 (94%) had eventual treatment success reported. Eleven subjects were reported to have received anti-hemorrhagics (eg. rFVIIa, activated <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span>-complex concentrate, tranexamic acid) prior to first treatment with OBIZUR. Of these 11 subjects, eight had eventual successful treatment (73%).</p>
<p>The median dose per infusion to successfully treat the primary <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episode was 133 units per kg and a median total dose of 1523 units per kg. In the initial 24 hour period, a median of 3 infusions (median dose 200 U/kg) were utilized in the clinical study. When treatment was required beyond 24 hours, a median of 10.5 infusions (median dose 100 U/kg) were given for a median of 6 days to control a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episode.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_58486925-0463-4820-9137-5a65da963989"></a><a name="section-12"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Italics">How Supplied</span></p>
<p>OBIZUR is supplied as a white lyophilized powder in single-use vials in the following package sizes: </p>
<table width="100%">
<col width="24%">
<col width="23%">
<col width="23%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Nominal Strength</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Package Size</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Kit NDC</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>500 units</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1-vial package</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0944-5001-01</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>500 units</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5-vial package</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0944-5001-05</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt> </dt>
<dd>500 units</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10-vial package</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0944-5001-10</p></td>
</tr>
</tbody>
</table>
<p>Each package contains one package insert and appropriate number of each of the components listed below correlating to the vial package size: </p>
<dl>
<dt>•</dt>
<dd>Single-use vial of OBIZUR [NDC 0944-5011-01]</dd>
<dt>•</dt>
<dd>Pre-filled syringe with 1 mL Sterile Water for Injection [NDC 0944-0011-01]</dd>
<dt>•</dt>
<dd>Vial adapter with filter</dd>
</dl>
<p>The actual amount of OBIZUR in units is stated on the label of each vial.  </p>
<p><span class="Italics">Storage and Handling</span></p>
<dl>
<dt>•</dt>
<dd>Store OBIZUR at refrigeration temperature of 2° to 8°C [36° to 46°F].  Do not freeze.</dd>
<dt>•</dt>
<dd>Store vials in the original package to protect from light.</dd>
<dt>•</dt>
<dd>Do not use beyond the expiration date printed on the carton or vial.</dd>
<dt>•</dt>
<dd>Use OBIZUR within 3 hours after reconstitution.  Discard any unused reconstituted product if not used within 3 hours after reconstitution.</dd>
<dt>•</dt>
<dd>Do not use OBIZUR if the reconstituted solution is cloudy or has particulate matter.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_18f4b046-36d0-419b-b8a4-9a84a28c3ac7"></a><a name="section-13"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<dl>
<dt>•</dt>
<dd>Advise patients to report any adverse reactions or problems following OBIZUR administration to their physician or healthcare provider.</dd>
</dl>
<p class="First">Baxter and Obizur are trademarks of Baxter International Inc., registered in the U.S. Patent and Trademark Office.</p>
<p>Manufactured by: </p>
<p><span class="Bold">Baxter Healthcare Corporation<br></span>Westlake Village, CA 91362 USA<br>U.S. License No. 140</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_db5d4735-02eb-4458-a37d-34378cee4671"></a><a name="section-14"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id716"></a><img alt="1-Vial Unit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69ccbb3-7648-4978-8c6d-7ca6b95a9b01&amp;name=image-03.jpg"><p class="MultiMediaCaption">1-Vial Package Unit Carton </p>
</div>
<p class="First">1-Vial Package Unit Carton </p>
<p>NDC 0944-5001-01</p>
<p><span class="Bold">OBIZUR</span></p>
<p>Antihemophilic Factor (Recombinant), Porcine Sequence</p>
<p>Single-use vial, lyophilized powder for solution</p>
<p><span class="Bold">For Intravenous Administration After Reconstitution Only</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>*Refer to actual potency</p>
<div class="Figure">
<a name="id-1127538622"></a><img alt="Unit Carton 0726589.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69ccbb3-7648-4978-8c6d-7ca6b95a9b01&amp;name=Unit%20Carton%200726589.jpg"><p class="MultiMediaCaption">5-Vial Package Unit Carton </p>
</div>
<p>5-Vial Package Unit Carton </p>
<p>NDC 0944-5001-05</p>
<p><span class="Bold">OBIZUR</span></p>
<p>Antihemophilic Factor (Recombinant), Porcine Sequence</p>
<p>Single-use vial, lyophilized powder for solution</p>
<p><span class="Bold">For Intravenous Administration After Reconstitution Only.</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>*Refer to actual potency</p>
<div class="Figure">
<a name="id-612516391"></a><img alt="Unit Carton 0726590.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69ccbb3-7648-4978-8c6d-7ca6b95a9b01&amp;name=Unit%20Carton%200726590.jpg"><p class="MultiMediaCaption">10-Vial Package Unit Carton</p>
</div>
<p>10-Vial Package Unit Carton</p>
<p>NDC 0944-5001-10</p>
<p><span class="Bold">OBIZUR</span></p>
<p>Antihemophilic Factor (Recombinant), Porcine Sequence</p>
<p>Single-use vial, lyophilized powder for solution</p>
<p><span class="Bold">For Intravenous Administration After Reconstitution Only.</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>*Refer to actual potency</p>
<div class="Figure">
<a name="id728"></a><img alt="3 mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69ccbb3-7648-4978-8c6d-7ca6b95a9b01&amp;name=image-04.jpg"><p class="MultiMediaCaption">3 mL Vial Label </p>
</div>
<p>3 mL Vial Label </p>
<p>NDC 0944-5011-01</p>
<p><span class="Bold">OBIZUR</span></p>
<p>Antihemophilic Factor (Recombinant), Porcine Sequence</p>
<p>Units/Vial:<br>Lot No:<br>Exp Date:</p>
<p>Units/Vial:<br>Lot No:<br>Exp Date:</p>
<p><span class="Bold">OBIZUR</span></p>
<p>Antihemophilic Factor (Recombinant), Porcine Sequence</p>
<p>3 mL vial, lyophilized powder,</p>
<p>sterile</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">For Intravenous</span></p>
<p><span class="Bold">Administration Only.</span></p>
<div class="Figure">
<a name="id740"></a><img alt="Sterile Water Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a69ccbb3-7648-4978-8c6d-7ca6b95a9b01&amp;name=image-05.jpg"><p class="MultiMediaCaption">Sterile Water Label</p>
</div>
<p>NDC 0944-0011-01</p>
<p><span class="Bold">1 mL</span></p>
<p>Sterile Water for Injection USP</p>
<p>Distributor: <span class="Bold">Baxter Healthcare Corporation</span></p>
<p>Manufactured by:</p>
<p>Vetter, Germany</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OBIZUR 		
					</strong><br><span class="contentTableReg">antihemophilic factor porcine, b-domain truncated recombinant kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-5001</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-5001-01</td>
<td class="formItem">1  in 1 CARTON; Combination Product Type = C102842</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0944-5001-05</td>
<td class="formItem">1  in 1 CARTON; Combination Product Type = C102842</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0944-5001-10</td>
<td class="formItem">1  in 1 CARTON; Combination Product Type = C102842</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">167 VIAL, GLASS </td>
<td class="formItem">500 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 1</td></tr>
<tr><td class="contentTableTitle">
<strong>OBIZUR 		
					</strong><br><span class="contentTableReg">antihemophilic factor porcine, b-domain truncated recombinant injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-5011</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ANTIHEMOPHILIC FACTOR PORCINE, B-DOMAIN TRUNCATED RECOMBINANT</strong> (ANTIHEMOPHILIC FACTOR PORCINE, B-DOMAIN TRUNCATED RECOMBINANT) </td>
<td class="formItem">ANTIHEMOPHILIC FACTOR PORCINE, B-DOMAIN TRUNCATED RECOMBINANT</td>
<td class="formItem">500 [USP'U]  in 3 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TROMETHAMINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TROMETHAMINE HYDROCHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-5011-01</td>
<td class="formItem">3 mL in 1 VIAL, GLASS; Combination Product Type = C102842</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125512</td>
<td class="formItem">10/23/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125512</td>
<td class="formItem">10/23/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Baxter Healthcare Corporation
							(039121363)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Healthcare Corporation</td>
<td class="formItem"></td>
<td class="formItem">058355971</td>
<td class="formItem">MANUFACTURE(0944-5001)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Vetter Pharma Fertigung GmbH &amp; Co, KG</td>
<td class="formItem"></td>
<td class="formItem">344217323</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a69ccbb3-7648-4978-8c6d-7ca6b95a9b01</div>
<div>Set id: a69ccbb3-7648-4978-8c6d-7ca6b95a9b01</div>
<div>Version: 1</div>
<div>Effective Time: 20141023</div>
</div>
</div> <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
